Literature DB >> 14572201

Immunoassay for soluble RANKL (receptor activator of NF-kappaB ligand) in serum.

Gerhard Hawa1, Natascha Brinskelle-Schmal, Karin Glatz, Sonja Maitzen, Wolfgang Woloszczuk.   

Abstract

This paper describes a method for the direct measurement of human sRANKL (receptor activator of NF-kappaB ligand), a cytokine of the tumor necrosis factor superfamily, which is a key player in bone metabolism. Its role in the regulation of osteogenic disorders such as osteoporosis, Paget's disease and rheumatoid arthritis is being extensively discussed in the literature at present. We developed a highly specific, simple and reliable ELISA which allows the direct measurement of uncomplexed sRANKL in human serum. Assay characteristics such as analytical precision, sensitivity, interfering factors, sample stability and dilution linearity are shown. Reference values from healthy volunteers (n=57) were found to be between 0 and 2.7 pmol/l (10th-90th percentile) with a mean serum value of 1.3 pmol/l (median 0.9 pmol/l).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14572201

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  9 in total

1.  Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis.

Authors:  M Skoumal; G Kolarz; G Haberhauer; W Woloszczuk; G Hawa; A Klingler
Journal:  Rheumatol Int       Date:  2005-05-12       Impact factor: 2.631

2.  RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus.

Authors:  A C Bonfá; L P C Seguro; V Caparbo; E Bonfá; R M R Pereira
Journal:  Osteoporos Int       Date:  2015-01-22       Impact factor: 4.507

3.  The imbalance between osteoprotegerin and cathepsin K in the serum of patients with longstanding rheumatoid arthritis.

Authors:  Martin Skoumal; Günther Haberhauer; Gernot Kolarz; Gerhard Hawa; Wolfgang Woloszczuk; Anton Klingler; Franz Varga; Klaus Klaushofer
Journal:  Rheumatol Int       Date:  2007-12-13       Impact factor: 2.631

4.  The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.

Authors:  Anna Stern; Gail A Laughlin; Jaclyn Bergstrom; Elizabeth Barrett-Connor
Journal:  Eur J Endocrinol       Date:  2007-05       Impact factor: 6.664

5.  Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis.

Authors:  A Dovio; D Generali; M Tampellini; A Berruti; S Tedoldi; M Torta; S Bonardi; M Tucci; G Allevi; S Aguggini; A Bottini; L Dogliotti; A Angeli
Journal:  Osteoporos Int       Date:  2007-08-17       Impact factor: 4.507

6.  Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction.

Authors:  Martin Skoumal; Günther Haberhauer; Gernot Kolarz; Gerhard Hawa; Wolfgang Woloszczuk; Anton Klingler
Journal:  Arthritis Res Ther       Date:  2004-11-10       Impact factor: 5.156

Review 7.  Overview of RAW264.7 for osteoclastogensis study: Phenotype and stimuli.

Authors:  Lingbo Kong; Wanli Smith; Dingjun Hao
Journal:  J Cell Mol Med       Date:  2019-03-20       Impact factor: 5.310

8.  The impact of nonosteogenic factors on the expression of osteoprotegerin and RANKL during human fracture healing.

Authors:  Julia Starlinger; Georg Kaiser; Anita Thomas; Kambiz Sarahrudi
Journal:  Bone Joint Res       Date:  2019-08-02       Impact factor: 5.853

9.  Circulatory Levels of RANKL, OPG, and Oxidative Stress Markers in Postmenopausal Women With Normal or Low Bone Mineral Density.

Authors:  Fawaz Y Azizieh; Diaa Shehab; Khaled Al Jarallah; Renu Gupta; Raj Raghupathy
Journal:  Biomark Insights       Date:  2019-08-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.